The Cancer Genome Atlas

# Multi-center Mutation Calling in TCGA

David A. Wheeler,

#### TCGA Symposium May 13, 2014



# (The art of) Multi-center mutation calling

- Approaches to somatic mutation calling
- Early benchmarking of somatic mutation callers
- Early trials of 3-center calling and adoption of standards
- Current status of multi-center calling
- New developments in mutation calling



### Sources of error in sequencing data

- Base calling error
  - Randomly distributed after Q recalibration (GATK)
  - Largely reflected in the Q-values
  - Estimated error rates ~10<sup>-3</sup> per base (Illumina)
  - Filter most of it, except for calling in low allele fraction variants
- Mapping error and alignment ambiguities
  - Systematic
  - Depends on details of repeat structure of the genome
  - Repeat structure is different in tumor and normal
  - Depends on sequencing chemistry
  - <sup>3</sup> Produces high-quality variation

The Cancer Genome Atlas 🌐

# Variant "truth engines" – 1<sup>st</sup> generation

• Atlas-SNP (BCM: Yu et al.)

 $Pr(S_j | SNP, c) \times prior(SNP | c)$ 

 $\Pr(SNP \mid S_j, c)_j = \frac{1}{\Pr(S_j \mid SNP, c) \times prior(SNP \mid c) + \Pr(S_j \mid error, c) \times prior(error \mid c)}$ 

MuTect (BI: Cibulskis et al.)

$$LOD_T = \log_{10}\left(\frac{L[M_f^m]}{L[M_0]}\right) \ge \log_{10}\delta - \log_{10}\left(\frac{P(m,f)}{(1-P(m,f))}\right) = \theta_T$$

• Pebbles (UCSC: Ma et al.)

$$P(G_t, G_n) = \frac{n!}{n_A! n_T! n_G! n_C!} \prod P(d_i | G_T, G_N, c) \cdot \frac{n!}{n_A! n_T! n_G! n_C!} \prod P(d_i | G_n) \cdot P(G_n)$$

BaSSoVac (TGI: Wendl & Ding)

### Downstream processing

- Initial variation calls must be filtered by heuristic criteria
  - MuTect best documented 7 criteria



Cisbulskis et al. Nature Biotechnology 2013

#### **TCGA** Colorectal Cancer Genes





### Benchmark 1 ca Feb 2011

#### Strict: Somatic Calls Passing Filters

Loose: All Somatic Calls



The Cancer Genome Atlas

### Benchmark 2 ca March 2011



i ne Cancer Genome Atlas 🕀









me Atlas

### Colorectal adenocarcinoma





# Early benchmarking conclusion

- Discordance between callers was high
- High quality calls, as defined by one caller were missed by other callers.
- Multi-center mutation calling may ameliorate these issues

# Low concordance in (diploid) SNP calling







**Acute Myeloid Leukemia** 

# Lung Adenocarcinoma





Caller Validation (Indels):

Broad: 60% WashU: 60% UCSC: 60%

### Somatic mutations called by 3 centers (including Illumina and Solid, BI did not call on Solid)



#### Validation of 325 Illumina SMG SNV on Ion Torrent



# Meta caller developed based on multiple mutation callers calibrated by validation data

Kim and Speed BMC Bioinformatics 2013, 14:189 http://www.biomedcentral.com/1471-2105/14/189



#### **RESEARCH ARTICLE**

**Open Access** 

### Comparing somatic mutation-callers: beyond Venn diagrams

Su Yeon Kim<sup>1\*</sup> and Terence P Speed<sup>1,2\*</sup>



# 2012-3 formalization of multicenter calling

- Mutations callers are improving
- Different callers detect different events
- Validation cycles take too long and cause delay in submissions
- 3-center calling
  - Multiple caller stratify the calls into high to low quality
  - Initial time line allowed 6 weeks (now 3 weeks)

### Marker paper submission

- MAF contains 3 callers with annotation of which group provided each call. (column 3 of the MAF)
- Significantly Mutated Gene list (e.g. MutSig, MUSIC) uses calls supported by two-centers (which guarantee high accuracy).
- The resulting SMGs can be used for submission.



# Final publication includes validation

- Validation requires a second independent sequencing event.
- Visual inspection of reads (e.g., IGV) is not validation; however, visual inspection improves accuracy. MAF was designed to capture that in the "Verification" column.
- Validation results are captured in separate BAM files and submitted.
- Validation should include mutations in genes on SMG, and include mutations found by single
  caller. The Cancer Genome Atlas

# Adrenal cortical carcinoma 91 patients: SNVs

New callers can be easily added, and therefore have role in marker BI paper.

With 5 callers require 3/5 being tested.



## **Second Generation Mutation Callers**

- Increased sophistication in heuristic filters
- Increased sophistication in underlying genetic models

#### (poster #60)

Evolutionary Distance (d)  $\propto$ 

Substitution Rate ( $\mu$ )  $\times$  Tumor Development Time (t)

- MuSE HGSC/MDACC
  - Distance measure per position per sample reflecting mutation evolution
  - Uncertainty estimates based on Bayesian Markov model
- Viper Wash U
- MuTect v 2

"To" Tumor Sequence A C G T D ( - To Tok Tok)

"From"	А	( -	$\pi_C$	$\pi_G \kappa$	$\pi T$	
Reference	С	$\pi_A$	_	$\pi_G$	$\pi_T \kappa$	
Sequence	G	$\pi_A \kappa$	$\pi_C$	—	$\pi_T$	
eequeriee	т	$\pi_A$	$\pi_C \kappa$	$\pi_G$	- )	

- $\pi$ : allele fraction
- $\kappa$  : transition / transversion rate ratio
- $\mu$  : scaled substitution rate
- t : tumor development time



### Dream Challenge

#### Synapse contribute to the Cure

#### ICGC-TCGA DREAM Mutation Calling challenge \*

Synapse ID: syn312572

#### Single Nucleotide Variants

ID	Submission Name	Team	Status	SMC Challenge Eligible	Number of Calls (Censor:Chr1)	Number of Calls (All)	Sensitivity (Censor:Chr1)	Sensitivity (All)	Specificity (Censor:Chr1)	Specificity (All)	Balanced Accuracy (Censor:
2343085	MuTect - L10	Broad SMC	SCORED	YES	3225	3476	0.96708	0.96719	0.98388	0.98360	0.97548
2368537	LoFreq Somatic: beta-3-159 dbac	LoFreq Somatic - GIS	SCORED	NO	3179	3422	0.95093	0.94908	0.98144	0.98042	0.96619
2346677	nRex3 mpileup-gatk-ext	DellyTeam	SCORED	YES	3235	3489	0.95672	0.95757	0.97032	0.97019	0.96352
2350981	nRex4 mpileup-gatk-ext	DellyTeam	SCORED	YES	3340	3606	0.96586	0.96747	0.94880	0.94842	0.95733
2350983	nRex5 mpileup-gatk-ext	DellyTeam	SCORED	YES	3338	3604	0.96556	0.96719	0.94907	0.94867	0.95732
2367742	LoFreq Somatic: beta-3-159 dba	LoFreq Somatic - GIS	SCORED	NO	3119	3360	0.93386	0.93267	0.98237	0.98125	0.95811
2346241	nRex mpileup-gatk-ext	DellyTeam	SCORED	YES	3341	3600	0.96525	0.96549	0.94792	0.94806	0.95659
2350992	dmut0.set1.02_5	DMUT	SCORED	YES	3189	3442	0.94240	0.94286	0.96958	0.96833	0.95599
2350994	dmut0.set1.02_6	DMUT	SCORED	YES	3191	3444	0.94240	0.94286	0.96898	0.96777	0.95569
2350974	dmut0.set1.02_4	DMUT	SCORED	YES	3201	3454	0.94240	0.94286	0.96595	0.96497	0.95417
2367150	LoFreq Somatic: beta-3-159 db	LoFreq Somatic - GIS	SCORED	NO	3231	3482	0.94727	0.94569	0.96193	0.96008	0.95460
2347517	dmut0.set1.01_4	DMUT	SCORED	YES	3212	3464	0.94240	0.94286	0.96264	0.96218	0.95252
2367520	LoFreq Somatic: beta-3-159 b100 dba	LoFreq Somatic - GIS	SCORED	NO	3190	3435	0.93904	0.93833	0.96583	0.96565	0.95244
2367152	LoFreq Somatic: beta-3-159 db no-p1	LoFreq Somatic - GIS	SCORED	NO	3252	3503	0.94910	0.94738	0.95756	0.95604	0.95333
2350872	dmut0.set1.001_4	DMUT	SCORED	YES	3264	3523	0.94697	0.94795	0.95190	0.95118	0.94943
2347464	Dream_Set1_MuSE_Setting8	Wang-Wheeler-HGSC	SCORED	YES	3086	3329	0.91984	0.92079	0.97797	0.97777	0.94890

Forum Register Login

Sharing

Search

#### Synapse contribute to the cure

#### ICGC-TCGA DREAM Mutation Calling challenge \*

Synapse ID: syn312572

Wiki

Files

#### Single Nucleotide Variants

ID	Submission Name	Team	Status	SMC Challenge Eligible	Number of Calls (Censor:Chr1)	Sensitivity (Censor:Chr1)	Specificity (Censor:Chr1)	Balanced Accuracy (Censor:Chr1)
2363577	MuTect - L10F	Broad SMC	SCORED	YES	3850	0.96054	0.99273	0.97664
2385689	Dream_Set2_MuSE_Setting3	Wang-Wheeler-HGSC	SCORED	YES	3932	0.96004	0.97152	0.96578
2368737	Dream_Set2_MuSE_Setting2	Wang-Wheeler-HGSC	SCORED	YES	3805	0.94370	0.98686	0.96528
2375120	nRex	DellyTeam	SCORED	YES	3897	0.95124	0.97126	0.96125
2368734	Dream_Set2_MuSE_Setting1	Wang-Wheeler-HGSC	SCORED	YES	3844	0.94396	0.97711	0.96053
2367176	mutect_conta	SLC_platform	SCORED	YES	3911	0.94999	0.96650	0.95825
2367734	nRex mpileup-gatk-exta	DellyTeam	SCORED	YES	4006	0.95979	0.95332	0.95655
2400705	LoFreq Somatic: beta-4-50- g2ce040e t-a5 n-a3p	LoFreq Somatic - GIS	SCORED	NO	3801	0.93365	0.97737	0.95551

Forum Register Login

Sharing

Search

Synapse contribute to the Cure

#### ICGC-TCGA DREAM Mutation Calling challenge \*

Synapse ID: syn312572

#### Single Nucleotide Variants

ID	Submission Name	Team	Status	SMC Challenge Eligible	Number of Calls (Censor:ChrMask)	Sensitivity (Censor:ChrMask)	Specificity (Censor:ChrMask)	Balanced Accuracy (Censor:ChrMask)	
2470044	viper.v4	WashU	SCORED	YES	5876	0.90987	0.98962	0.94975	
2468117	viper.v3d	WashU	SCORED	YES	5904	0.91144	0.98662	0.94903	
2453885	Dream_Set3_MuSE_Setting4	Wang-Wheeler-HGSC	SCORED	YES	6050	0.92270	0.97471	0.94871	
2456287	MuTectL700W	Broad SMC	SCORED	YES	5942	0.91410	0.98317	0.94863	
2456202	MuTectL750W	Broad SMC	SCORED	YES	5903	0.91066	0.98594	0.94830	
2463211	Dream_Set3_MuSE_Setting6	Wang-Wheeler-HGSC	SCORED	YES	5996	0.91738	0.97782	0.94760	
2460162	viper.v2	WashU	SCORED	YES	5836	0.90455	0.99058	0.94756	
2467165	viper.v3c	WashU	SCORED	YES	5918	0.91034	0.98310	0.94672	
2460633	Dream_Set3_MuSE_Setting5	Wang-Wheeler-HGSC	SCORED	YES	5926	0.91097	0.98245	0.94671	
2470029	varScan.snv.v7c	WashU	SCORED	YES	5819	0.90189	0.99055	0.94622	
2463247	Dream_Set3_MuSE_Setting8	Wang-Wheeler-HGSC	SCORED	YES	6156	0.92787	0.96329	0.94558	
2453883	Dream_Set3_MuSE_Setting3	Wang-Wheeler-HGSC	SCORED	YES	5836	0.90174	0.98749	0.94461	
2420793	mutect_noise	SLC_platform	SCORED	YES	5748	0.89407	0.99408	0.94408	

Search

Forum Register Login

Sharing

### Conclusions

- TCGA paradigm mutation discovery is improved by multicenter calling
  - Decreased FN rates
  - Delivers a set of somatic SNVs of calibrated accuracy
  - Accelerates submission of marker papers
  - Stimulates development of new mutation callers by providing 'benchmarking' on the fly.
  - A formal "meta-caller" was developed which may be useful in retrospectively refining mutation calls from TCGA tumor sets
- Multi-center mutation calling has not been applied to other mutation modalities. Needs to be tested.



### Acknowledgments

- Wash U
  - Li Ding
  - Chris Miller
  - Mike McClellan
  - Cyriac Kandoth
- Broad
  - Gaddy Getz
  - Mara Rosenberg
  - Kris Cisbulskis

- MD Anderson
  - Wenyi Wang
  - Yu Fan
- BCM
  - Liu Xi
  - Caleb Davis

### Clear cell renal cell carcinoma (KIRK)



>500 patients 14330 (41.79% of 420) 4994 11518 (88.35% of 758) (93.83% of 292) 25038 (93.39% of 1848) 126352 17158 (24.83% of 604) (59.64% of 114) 2672 (89.19 of 74) UCSC Broad